<DOC>
	<DOCNO>NCT02684383</DOCNO>
	<brief_summary>Infection dengue virus lead cause hospitalization death child many tropical Asian country , development dengue vaccine top health priority . This study evaluate safety immunogenicity live attenuate monovalent dengue virus vaccine ( rDEN3Δ30 ) healthy adult history previous flavivirus infection .</brief_summary>
	<brief_title>Evaluation Safety Immunogenicity rDEN3Δ30 , Live Attenuated Monovalent Dengue Virus Vaccine</brief_title>
	<detailed_description>The purpose study evaluate safety immunogenicity live attenuate monovalent dengue virus vaccine ( rDEN3Δ30 ) healthy flavivirus-naive adult . Participants randomly assign receive rDEN3Δ30 vaccine placebo Day 0 . Study visit occur Days 2 , 4 , 6 , 8 , 10 , 12 , 14 , 16 , 21 , 28 , 56 , 90 , 180 . Visits include physical examination blood collection . All participant record temperature 3 time day Day 0 Day 16 . Some participant may admit clinic inpatient ( overnight ) stay first 16 day study .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult male female 18 50 year age , inclusive . Good general health determine physical examination , laboratory screening , review medical history . Available duration study , approximately 26 week postvaccination . Willingness availability potential inpatient admission inpatient unit follow receipt rDEN3Δ30 . Willingness participate study evidence sign informed consent document . Females Only : Female subject childbearing potential willing use effective contraception begin long enough dosing ensure method specific efficacy duration trial . Reliable method contraception include hormonal birth control , condom spermicide , diaphragm spermicide , surgical sterilization , intrauterine device , abstinence ( great equal 6 month since last sexual encounter ) . All female subject consider childbearing potential except hysterectomy , tubal ligation , tubal coil ( least 3 month prior vaccination ) , postmenopausal status document least 1 year since last menstrual period . Females Only : Currently pregnant , determine positive betahuman chorionic gonadotropin ( HCG ) test , breastfeed . Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease history , physical examination , and/or laboratory study . Behavioral , cognitive , psychiatric disease opinion investigator affect ability subject understand cooperate requirement study protocol . Confirmed screen laboratory value Grade 1 absolute neutrophil count ( ANC ) , alanine aminotransferase ( ALT ) , serum creatinine , define protocol . Confirmation obtain repeat test ensure abnormal value due aberrancy . Any condition opinion investigator would jeopardize safety right subject participate trial would render subject unable comply protocol . Any significant alcohol drug abuse past 12 month cause medical , occupational family problem , indicate subject history . History severe allergic reaction anaphylaxis . Severe asthma ( emergency room visit hospitalization within last 6 month ) . HIV infection , screen confirmatory assay . Hepatitis C virus ( HCV ) infection , screen confirmatory assay . Hepatitis B virus ( HBV ) infection , hepatitis B surface antigen ( HBsAg ) screen . Any known immunodeficiency syndrome . Use anticoagulant medication . Use corticosteroid ( exclude topical nasal ) immunosuppressive drug within 28 day prior follow vaccination . Immunosuppressive dose corticosteroid define great equal 10 mg prednisone equivalent per day great equal 14 day . Receipt live vaccine within 28 day kill vaccine within 14 day prior vaccination anticipate receipt vaccine 28 day follow vaccination . Asplenia . Receipt blood product within past 6 month , include transfusion immunoglobulin anticipate receipt blood product immunoglobulin 28 day follow vaccination . History serologic evidence previous dengue virus infection flavivirus infection ( e.g. , yellow fever virus , St. Louis encephalitis virus , West Nile virus ) . Previous receipt flavivirus vaccine ( licensed experimental ) . Anticipated receipt investigational agent 28 day vaccination . Subject definite plan travel dengueendemic area study . Known allergy antipyretic . Refusal allow storage specimens future research . Other Treatments Ongoing The following criterion review day 28 56 postvaccination . If become applicable study , subject include immunogenicity evaluation , exclusionary visit . The subject , however , encourage remain study safety evaluation duration study . Ongoing Use investigational drug investigational vaccine study vaccine 28day period postvaccination . Chronic administration ( great equal 14 day ) steroid ( define prednisone equivalent great equal 10 mg per day ) , immunosuppressant , immunemodifying drug initiate 28day period postvaccination ( topical nasal steroid allow ) . Receipt license vaccine 28day period post vaccination . Receipt immunoglobulins and/or blood product 28day period post vaccination . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Dengue Vaccine</keyword>
</DOC>